Supporting data for: Low-cost drug discovery with engineered E. coli reveals an anti-mycobacterial activity of benazepril
Authors/Creators
- 1. INSERM U1284, Université de Paris, Center for Research and Interdisciplinarity (CRI), Paris, France
- 2. INSERM, Sorbonne Université, Université de Paris, Centre de Recherche des Cordeliers (CRC), Paris, France
- 3. Current address: USR 3756 IP CNRS, Institut Pasteur, Paris, France
Description
Supporting data for Low-cost drug discovery with engineered E. coli reveals an anti-mycobacterial activity of benazepril
The associated reference describes our work developing TESEC Mtb ALR, a genetically engineered strain of E. coli expressing the enzyme ALR derived from Mtb. We used the TESEC Mtb ALR strain in a high-throughput drug screen and identified benazepril as targeted inhibitor of the ALR enzyme. We then performed additional experiments to characterize the activity of benazepril against E. coli, Mtb and purified enzymes.
These files include growth measurements, biochemical assays and other forms of biological data. They are packaged together with scripts used to analyze the data and present them in figures. Our goal in creating this archive was to present our complete analysis pipeline in the spirit of open science. It is not intended to be a stand-alone resource. Consult the associated manuscript for protocols, units of measurement and other essential technical context.
Our scripts were written for Python 3.8. The raw data is presented as human-readable .csv files intended to be imported as Pandas DataFrames. Some data is also packaged as Python dictionaries saved with the Pickle package.
Files
Fig 1.pdf
Files
(15.4 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:1c124cb9e84a8d926528c47b2ced6deb
|
889.0 kB | Preview Download |
|
md5:3707ed9e44da0981b06fc70d1225a1ba
|
921.1 kB | Preview Download |
|
md5:f626830d5a88f119b8a770e0f9e4d168
|
934.7 kB | Preview Download |
|
md5:078788ab0977244204626170af00a2fd
|
1.6 MB | Preview Download |
|
md5:8b6a00003b349c1731fc6e0651d7dbbe
|
858.5 kB | Preview Download |
|
md5:f701e39516dfa1c6cf9980efb4247a12
|
846.3 kB | Preview Download |
|
md5:9f004a1d1be8c5eb6b63d70b35529f12
|
18.6 kB | Download |
|
md5:df081286770dbeac277939b7bf8f5014
|
16.1 kB | Download |
|
md5:f2b6b3ce8e08e19be84168ddb4bca867
|
9.5 kB | Download |
|
md5:bfa5369e84abef57abaaa3201743a1a5
|
25.2 kB | Download |
|
md5:2caa46f038db1bb24894aba68758ecab
|
11.5 kB | Download |
|
md5:82cb103ca2d98f01e6220b0688c449d3
|
4.9 kB | Download |
|
md5:a8e123c5e07cdc9c8faa3db0f4f25fed
|
8.9 kB | Preview Download |
|
md5:56d4741c561e1a3c44e813583913140b
|
75 Bytes | Preview Download |
|
md5:af6f79d6739c093803198c62a5c82b9b
|
9.3 MB | Preview Download |
|
md5:76e4ef9f3c5a2548b5bf5c312dd70219
|
7.1 kB | Preview Download |
Additional details
Related works
- Cites
- Preprint: 10.1101/2021.03.26.437171 (DOI)
References
- Bongaerts N et al. (2021) Low-cost drug discovery with engineered E. coli reveals an anti-mycobacterial activity of benazepril. bioRxiv 2021.03.26.437171. doi: https://doi.org/10.1101/2021.03.26.437171